Switch theme
Sign up to access all valuation multiples
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
2001
104.2K+
LTM Revenue $185B
LTM EBITDA $11.3B
$101B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Elevance Health has a last 12-month revenue (LTM) of $185B and a last 12-month EBITDA of $11.3B.
In the most recent fiscal year, Elevance Health achieved revenue of $177B and an EBITDA of n/a.
Elevance Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Elevance Health valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $185B | XXX | $177B | XXX | XXX | XXX |
| Gross Profit | $165B | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | $11.3B | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | n/a | XXX | XXX | XXX |
| EBIT | $9.2B | XXX | n/a | XXX | XXX | XXX |
| EBIT Margin | 5% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | $7.7B | XXX | $6.0B | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $22.9B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, Elevance Health's stock price is $348.
Elevance Health has current market cap of $78.6B, and EV of $101B.
See Elevance Health trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $101B | $78.6B | XXX | XXX | XXX | XXX | $33.77 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, Elevance Health has market cap of $78.6B and EV of $101B.
Elevance Health's trades at 0.6x EV/Revenue multiple, and n/a EV/EBITDA.
Equity research analysts estimate Elevance Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elevance Health has a P/E ratio of 10.2x.
See valuation multiples for Elevance Health and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $78.6B | XXX | $78.6B | XXX | XXX | XXX |
| EV (current) | $101B | XXX | $101B | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | n/a | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | n/a | XXX | XXX | XXX |
| EV/Gross Profit | 0.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.2x | XXX | 13.1x | XXX | XXX | XXX |
| EV/FCF | 16.9x | XXX | 22.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialElevance Health's last 12 month revenue growth is 9%
Elevance Health's revenue per employee in the last FY averaged $1.7M, while opex per employee averaged n/a for the same period.
Elevance Health's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Elevance Health's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Elevance Health and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| ADNIC | XXX | XXX | XXX | XXX | XXX | XXX |
| Aegon | XXX | XXX | XXX | XXX | XXX | XXX |
| ASR Nederland | XXX | XXX | XXX | XXX | XXX | XXX |
| NN Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Challenger | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elevance Health acquired XXX companies to date.
Last acquisition by Elevance Health was XXXXXXXX, XXXXX XXXXX XXXXXX . Elevance Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Elevance Health founded? | Elevance Health was founded in 2001. |
| Where is Elevance Health headquartered? | Elevance Health is headquartered in United States of America. |
| How many employees does Elevance Health have? | As of today, Elevance Health has 104.2K+ employees. |
| Who is the CEO of Elevance Health? | Elevance Health's CEO is Ms. Gail Koziara Boudreaux. |
| Is Elevance Health publicy listed? | Yes, Elevance Health is a public company listed on NYS. |
| What is the stock symbol of Elevance Health? | Elevance Health trades under ELV ticker. |
| When did Elevance Health go public? | Elevance Health went public in 2001. |
| Who are competitors of Elevance Health? | Similar companies to Elevance Health include e.g. ADNIC, Aegon, ASR Nederland, NN Group. |
| What is the current market cap of Elevance Health? | Elevance Health's current market cap is $78.6B |
| What is the current revenue of Elevance Health? | Elevance Health's last 12 months revenue is $185B. |
| What is the current revenue growth of Elevance Health? | Elevance Health revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Elevance Health? | Current revenue multiple of Elevance Health is 0.5x. |
| Is Elevance Health profitable? | Yes, Elevance Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Elevance Health? | Elevance Health's last 12 months EBITDA is $11.3B. |
| What is Elevance Health's EBITDA margin? | Elevance Health's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Elevance Health? | Current EBITDA multiple of Elevance Health is 9.0x. |
| What is the current FCF of Elevance Health? | Elevance Health's last 12 months FCF is $6.0B. |
| What is Elevance Health's FCF margin? | Elevance Health's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Elevance Health? | Current FCF multiple of Elevance Health is 16.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
